NABI Share Price

Open 1.77 Change Price %
High 1.83 1 Day 0.01 0.56
Low 1.77 1 Week 0.00 0.00
Close 1.80 1 Month 0.00 0.00
Volume 627989 1 Year 0.00 0.00
52 Week High 0.10
52 Week Low 0.00
NABI Important Levels
Resistance 2 1.86
Resistance 1 1.83
Pivot 1.80
Support 1 1.77
Support 2 1.74
NASDAQ USA Most Active Stocks
DRYS 2.24 -4.68%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
MYRX 0.10 100.00%
LOCM 0.09 50.00%
CEMP 4.05 28.57%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
IPCI 2.55 18.60%
QKLS 0.15 15.38%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
GMETP 0.70 -59.54%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
EDMC 0.01 -50.00%
QTWW 0.08 -50.00%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Nabi Biopharmaceuticals (NASDAQ: NABI)

NABI Technical Analysis 4
As on 8th Nov 2012 NABI Share Price closed @ 1.80 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.74 & Strong Buy for SHORT-TERM with Stoploss of 1.73 we also expect STOCK to react on Following IMPORTANT LEVELS.
NABI Target for February
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
Nabi Biopharmaceuticals ( NASDAQ USA Symbol : NABI )
Sector : Health Care Biotechnology: Biological Products (No Diagnostic Substances) And Other Stocks in Same Sector
BPAX
1.09 0.01 (0.93 %)
LT : Strong Sell
ST : Sell
LIFE
3.38 -0.04 (-1.17 %)
LT : Buy
ST : Buy
NABI
1.80 0.01 (0.56 %)
LT : Buy
ST : Strong Buy
ONXX
124.70 0.00 (0.00 %)
LT : Strong Buy
ST : Sell
SGMO
4.00 0.15 (3.90 %)
LT : Sell
ST : Buy
NABI Other Details
Segment EQ
Market Capital 49857964.00
Sector Health Care Biotechnology: Biological Products (No Diagnostic Substances)
Industry
Offical website
NABI Address
NABI
N/A
Interactive Technical Analysis Chart Nabi Biopharmaceuticals ( NABI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Nabi Biopharmaceuticals
NABI Business Profile
Biota Pharmaceuticals, Inc., formerly Nabi Biopharmaceuticals, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza. Biota developed the neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. The Company�s researches include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir, is approved for marketing in Japan. The Company�s products include Zanamivir, Inavi, Phoslyra, BioStar OIA FLU and BioStar OIA FLU A/B. Biota, together with its Japanese based partner, Daiichi Sankyo, have developed an inhaled antiviral compounds for influenza, called long acting inhaled neuraminidase inhibitors (LANI).